Johns Hopkins ABX Guide
Telavancin
INDICATIONS
FDA
FDA
- Complicated skin and skin structure infections caused by susceptible Gram-positive bacteria (S. aureus including MRSA, S. pyogenes, other Strep species [S. agalactiae, S. anginosusgroup], or vancomycin sensitive E. faecalis).
- HAP and VAP caused by susceptible isolates of S. aureus.
- It should be reserved for use when alternative agents are not suitable.
NON-FDA APPROVED USES
NON-FDA APPROVED USES
- S. aureus bacteremia and right-sided endocarditis randomized trial comparing telavancin with standard therapy is under way (NCT02208063)
There's more to see -- the rest of this topic is available only to subscribers.
Last updated: October 2, 2018
Citation
Avdic, Edina, and Paul A Pham. "Telavancin." Johns Hopkins ABX Guide, The Johns Hopkins University, 2018. Pediatrics Central, peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin.
Avdic E, Pham PA. Telavancin. Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin. Accessed May 2, 2025.
Avdic, E., & Pham, P. A. (2018). Telavancin. In Johns Hopkins ABX Guide. The Johns Hopkins University. https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin
Avdic E, Pham PA. Telavancin [Internet]. In: Johns Hopkins ABX Guide. The Johns Hopkins University; 2018. [cited 2025 May 02]. Available from: https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Telavancin
ID - 540538
A1 - Avdic,Edina,Pharm.D.
AU - Pham,Paul,Pharm.D. BCPS
Y1 - 2018/10/02/
BT - Johns Hopkins ABX Guide
UR - https://peds.unboundmedicine.com/pedscentral/view/Johns_Hopkins_ABX_Guide/540538/all/Telavancin
PB - The Johns Hopkins University
DB - Pediatrics Central
DP - Unbound Medicine
ER -
